This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Asia
19 - 21 October, 2026
The Westin Miyako KyotoKyoto, Japan

Maximilian Brinkhaus
Senior Scientist II at argenx, Belgium
Speaker

Profile

Before joining argenx, I researched the impact of IgG Fc and format engineering on Fc receptor interactions and the downstream effects on IgG cellular trafficking in close collaboration with the company. I officially joined argenx in 2022, where I now serve as a group lead in R&D, leading antibody development projects from selections to IND enabling studies.

Agenda Sessions

  • FcγRs mediate IgG internalization and delivery to FcRn

    15:30